Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

enter at the University of Texas Health Science Center in San Antonio; - Poster presentations at the ASCO 2010 Annual Meeting covering the structures of a "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors" and a "Phase I/II trial of reovirus serotype 3-Dearing strain in patients with recurrent ovarian cancer"; - The decision to initiate a U.S. Phase I study of REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022); - Completion of Phase I patient enrollment in a Phase I/II clinical trial to investigate the use of REOLYSIN for patients with recurrent malignant gliomas (REO 007);

Preclinical Program

        -  A paper entitled "Antiangiogenic cancer therapy combined with
           oncolytic virotherapy leads to regression of established tumors in
           mice," co-senior authored by Dr. Richard Vile of the Department of
           Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin
           Harrington of the Institute of Cancer Research, London, UK, was
           published in the online version of the Journal of Clinical
           Investigation;
        -  A poster presentation at the AACR Annual Meeting entitled
           "Molecular pathways associated with REOLYSIN and gemcitabine
           synergy in ras-mutated human HCT116 cells," covering work done to
           better understand the mechanisms associated with the cytotoxic
           synergies in this combined approach in colorectal cancer cell
           lines;
        -  A poster presentation at the AACR Annual Meeting entitled "The
          
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... OLIGOMERIX, Inc. today announced the receipt of a ... $323,000 from the National Institute on Aging of the ... program is to develop novel biomarker assays for Alzheimer,s ... apolipoprotein E (apoE) proteins will be monitored in cerebrospinal ...
... FRANCISCO, Feb. 25 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic ... for the treatment of atherosclerosis. This patent is ...
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ), ... manufacturing and marketing biopharmaceutical products, today,announced that it ... and,full year ended December 31, 2008 after the ... Following the earnings announcement, ...
Cached Biology Technology:OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 3VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 43SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... raise questions about why such losses matter and why ... traditionally responded to such questions by citing societal benefits ... like controlling pests and diseases, promoting the productivity of ... many others. Nevertheless, many of these presumed benefits are ...
... Battery technology hasn,t kept pace with advancements in portable ... One revolutionary concept being pursued by a team of ... capable of converting movement from humans or found in ... variable capacitor generators known as "dielectric elastomer generators" (DEGs) ...
... Rochelle, NY, April 6, 2011 The successful ... survival and reduce the risk of neurological consequences ... the premier issue of Therapeutic Hypothermia and ... published by Mary Ann Liebert, Inc. This groundbreaking ...
Cached Biology News:Precedent-setting evidence of the benefits of biodiversity 2Precedent-setting evidence of the benefits of biodiversity 3Precedent-setting evidence of the benefits of biodiversity 4Replacing batteries may become a thing of the past, thanks to 'soft generators' 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Antibody Plate is a 96-well ELISA-compatible ... This antibody (mouse IgG 1 ) ... glutathione-S-transferase (GST), and binds with ... fusion protein in which the tag ...
... Testing Laboratory (RTL) can provide you ... years. ,,Microbial method development and validation ... the conditions of your GMP manufacturing ... products,,We offer a full spectrum of ...
... QED Bioscience has over 23 years of ... lines. We have made antibodies to large ... and viral antigens, and plasmid DNA-encoded antigens. ... is unique, so our hybridoma development programs ...
Biology Products: